Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 64 references it cites were found in a registry or an index; 11 of the 30 sources its claims cite were checked for support.

Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review

Open access

Abstract

OBJECTIVE: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD. DATA SOURCES: PubMed and EMBASE searches were conducted on July 30, 2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. STUDY SELECTION: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). DATA EXTRACTION: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. RESULTS: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. CONCLUSIONS: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.

Overview

CoChat Summary

TL;DR

This systematic review of 43 reports found that antidepressant monotherapy and augmentation therapy may improve cognition in major depressive disorder, but only 12% of individually analyzed cognitive changes favored active treatment over placebo or untreated healthy controls. The authors conclude that wide variability in study design and treatment duration warrants cautious interpretation and that more definitive research is needed.

Key findings

  • Across 43 reports (4,828 participants total), most individual studies reported some cognitive benefit with pharmacotherapy, but there was no consistent pattern across specific cognitive domains; only 12% of individually analyzed changes (20/168) favored active treatment over placebo or untreated healthy controls, while 4% (7/168) favored the control condition.
  • Sample-weighted mean effect sizes showed a small effect favoring active treatment for verbal memory with monotherapy, and a small effect favoring placebo for processing speed; with augmentation therapy, the largest treatment effect was for visual memory (moderate), with small effects favoring active treatment for visual processing, verbal memory, processing speed, executive function, and cognitive control, and large effects favoring placebo for memory.
  • Significant benefit was reported in 7 of 8 placebo-controlled monotherapy studies and 5 of 7 placebo-controlled augmentation studies; in 10 of 11 active-comparator trials, sertraline was consistently superior to nortriptyline in 3 studies and to fluoxetine in 2.
  • Studies were highly heterogeneous: median 50 participants (IQR 21–143), median duration 8 weeks (IQR 6–12), and inconsistent domain categorization (eg, the Stroop test was labeled as executive function, processing speed, or attention in different studies).

Methods

  • Systematic review with PubMed and EMBASE searches conducted July 30, 2013, for English-language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD; 4 searches yielded 1,032 hits (PubMed n = 759; EMBASE n = 273), yielding 43 research reports (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label]; 12 augmentation [7 placebo-controlled, 5 open-label]).
  • Effect sizes (Cohen d) were calculated for treatment differences in change from baseline for cognitive endpoints from trials with a placebo, healthy control, or active comparator that adequately reported data; sample-weighted mean effect sizes with 95% CIs were computed per cognitive domain. Published abstracts were excluded from effect size assessment.
  • Effect sizes were calculable for 168 cognitive measures from 15 of the 43 publications (8 monotherapy, 4 augmentation, plus data requested from authors of 3 more).

Limitations

  • Stated by the authors: effect sizes were estimated using the pooled standard deviation at end of study, which may over- or underestimate the true effect size; the number of measures per sample-weighted mean effect size was ≤ 3 for all but 1 monotherapy domain and ≤ 4 in 7 of 9 augmentation domains; high variability in study design and data presentation; many studies were small or assessed selected subgroups (eg, elderly, specific comorbidities), limiting generalizability; studies were generally short, leaving long-term effects uncertain; statistical methodology was inconsistent, with only 7 reports describing correction for multiple comparisons; several studies relied solely on the MMSE, which has ceiling effects and no alternate form; domain categorization was inconsistent; the review was restricted to PubMed and EMBASE; inclusion of abstracts (less rigorous peer review) is a limitation, though abstract data were excluded from effect size analyses; publication bias could influence findings.
  • Evident from the text: with the exception of one report (Madhoo et al) in a partially or fully remitted population, studies assessed cognition in the presence of mild to severe depressive symptoms, making it difficult to establish whether cognitive improvement was independent of clinical response; studies in elderly individuals generally did not distinguish cognitive decline due to aging from depression-related impairment; comorbid medical conditions were generally not addressed (except Wise et al).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.4088/jcp.13r08609

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 3 Effect Sizes With 95% CIs for Augmentation Therapy Versus Placebo
Figure 3 Effect Sizes With 95% CIs for Augmentation Therapy Versus PlaceboFrom the PDF
Figure 4 Sample-Weighted Effect Sizes With 95% CIs Across Cognitive Function Domains
Figure 4 Sample-Weighted Effect Sizes With 95% CIs Across Cognitive Function DomainsFrom the PDF

Verification

Claims the paper makes

10 Valid · 0 Not valid · 22 Not checked · 61 Own results and interpretations

51 more claims · 1 with their cited sources checked

Create a free account to see all 93 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 64 references

Research works printed but not linked: 3

  1. [36]36. Alev L, Altin M, Ozbek K, et al. Effect of duloxetine on functional outcomes in patients with major depressive disorder. Klinik Psikofarmakoloji Bulteni. 2011;21:S115.
  2. [38]38. Hashemian F, Tabatabayi MS, Sharifi A, et al. Comparison of the effects of bupropion and fluoxetine on reaction time in adults with major depressive disorder in a 4-week, single-blind study. Klinik Psikofarmakoloji Bulteni. 2011;21:S113.
  3. [40]40. Murrough JW, Wan LB, Glicksberg B, et al. Ketamine and neurocognition in depression: the modulating effects of lamotrigine. Neuropsychopharmacology. 2012;38:S375.

Cited by

See all 109

Metadata

Authors
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M.
Affiliations
  • Duke University (US)
  • Duke Medical Center (US)
  • Dartmouth College (US)
Corresponding author
Keefe, Richard S. E.
Venue
The Journal of Clinical Psychiatry
Published
2014-07-08
Volume
75
Issue
08
Pages
864-876
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2030109188
Cited by
107
References
64
Citations by year
2026: 2 · 2025: 8 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 13 · 2020: 7 · 2019: 8 · 2018: 14 · 2017: 10 · 2016: 18 · 2015: 10 · 2014: 2
FWCI
1.71
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
major depressive disorder, cognitive impairment, pharmacotherapy, antidepressants, augmentation therapy, verbal memory, visual memory, cognitive function, remission
MeSH terms
Antidepressive Agents, Cognition Disorders, Major Depressive Disorder, Drug Therapy, Combination, Humans, Neuropsychological Tests, Psychotropic Drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review. https://app.cochat.ai/papers/10.4088/jcp.13r08609
The paper
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014). Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13r08609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.